Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

The Vertos MILD™ Preliminary Patient Evaluation Study

Lumbar Spinal Stenosis

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.3 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Minimally Invasive Lumbar Decompression (MILD™) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Vertos Medical, Inc.
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS).
3.3
PRIMARY
Function as Measured Subjectively by the Oswestry Disability Index Patient Questionnaire
19.4
PRIMARY
Quality of Life as Measured by the PCS Subscale of the Short-form 12 Question (SF-12) Survey.
6.14

Summary

This is a single-center, open label, prospective clinical study to assess the clinical application and functional outcomes of symptomatic patients undergoing the Minimally Invasive Lumbar Decompression (MILD™) treatment for lumbar spinal stenosis. In this study, patient-reported outcomes over a 3 month period following treatment will be collected by the investigator. Periodic surveys for each study subject's pain, functional status, quality of life and physical examination will track outcomes following MILD™ treatment.

Eligibility Criteria

Inclusion Criteria

  • Symptomatic lumbar spinal stenosis (LSS) primarily caused by dorsal element hypertrophy.
  • Prior failure of conservative therapy.
  • Radiologic evidence of LSS (L3-L5), Ligamentum flavum > 2.5 mm, confirmed by pre op MRI and/or CT.
  • Central canal cross sectional area < 100mm2.
  • Anterior listhesis < 2 - 3mm.
  • Able to walk at least 10 feet unaided before being limited by pain.
  • Available to complete 12 weeks of follow-up.
  • A signed Informed Consent Form is obtained from the patient.
  • Adults ≥ 18 years of age.

Exclusion Criteria

  • Prior surgery at intended treatment level.
  • History of recent spinal fractures with concurrent pain symptoms.
  • Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
  • Significant disk protrusion or osteophyte formation.
  • Excessive facet hypertrophy.
  • Bleeding disorders and/or current use of anti coagulants.
  • Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.
  • Epidural steroids within prior three weeks.
  • Inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (COPD), obesity, etc.).
  • Any potential wound healing pathologies that may compromise outcomes, including: diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.
  • Dementia and/or inability to give informed consent.
  • Pregnancy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00749073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search